L19-TNF is an antibody-fusion protein for the targeting of the alternatively-spliced EDB domain of fibronectin [41], that shows potent antitumor activity in preclinical models of cancer [13–15] and is now being investigated in clinical trials [18, 22, 42]. Here, TNF is linked to cancer.